Jazz Pharmaceuticals PLC (JAZZ)

Drugs • Health Care

Stock AI

News & Reports

August 03, 2026 Jazz Pharmaceuticals PLC Reports Strong Q2 2026 Results Amid Strategic Growth Initiatives Jazz Pharmaceuticals PLC's Q2 2026 report highlights a remarkable turnaround with $1.20 billion in revenue and $192.8 million in net income. The company's strategic investments in R&D and market expansion, particularly in rare diseases and oncology, underscore its commitment to innovation and operational excellence.

July 20, 2026 Jazz Pharmaceuticals Set to Announce Second Quarter Financial Results Jazz Pharmaceuticals is set to report its second quarter financial results on August 3, 2026. A live webcast will follow for stakeholders to gain insights into the company’s performance and strategic direction.

June 17, 2026 Jazz Pharmaceuticals and AbCellera Team Up to Advance Cancer Treatments Jazz Pharmaceuticals has announced a collaboration with AbCellera to develop T-cell engaging multispecific antibodies for GI cancers. This partnership aims to leverage cutting-edge technology to improve treatment outcomes for patients suffering from rare diseases.

June 16, 2026 Jazz Pharmaceuticals Unveils Late-Breaking Data on Xywav® at SLEEP 2026 At the SLEEP 2026 conference, Jazz Pharmaceuticals presented pivotal findings on Xywav®'s impact on narcolepsy and idiopathic hypersomnia. The research emphasizes individualized dosing and the drug's low-sodium formulation, which improves patient outcomes and addresses cardiometabolic risks.

June 12, 2026 Jazz Pharmaceuticals Releases Results of LAGOON Trial for Zepzelca® in Small Cell Lung Cancer Jazz Pharmaceuticals announced that the LAGOON trial for Zepzelca did not meet its primary endpoint of improving overall survival in small cell lung cancer. Despite the results, the safety profile remains consistent, and the company is focusing on its use in first-line maintenance therapy.

June 04, 2026 Jazz Pharmaceuticals Announces Promising Data Presentation at SLEEP 2026 Jazz Pharmaceuticals will present 21 abstracts, including late-breaking research on Xywav at the SLEEP 2026 conference. The studies focus on real-world applications and insights for treating narcolepsy and idiopathic hypersomnia, reflecting the company's commitment to patient-centered care.

May 27, 2026 Jazz Pharmaceuticals Announces Landmark HERIZON-GEA-01 Trial Results for Ziihera® Jazz Pharmaceuticals' HERIZON-GEA-01 trial reveals Ziihera® significantly improves survival outcomes for HER2-positive gastroesophageal adenocarcinoma. The trial shows increased progression-free and overall survival compared to standard treatments, marking a potential new standard of care.

May 05, 2026 Jazz Pharmaceuticals PLC Q1 2026 Report: A Transformative Quarter in Financial and Product Performance Jazz Pharmaceuticals' Q1 2026 report reveals a remarkable financial turnaround with a net income of $293.1 million and a 17.9% revenue increase to $1.06 billion. Key products like Xywav and Epidiolex showed strong sales growth, reinforcing the company's focus on innovative therapies for rare diseases.

May 05, 2026 Jazz Pharmaceuticals Reports Strong First Quarter 2026 Financial Results Jazz Pharmaceuticals announced a 19% increase in revenues for Q1 2026, achieving $1.1 billion. The company's pipeline advancements, including zanidatamab, position it for continued success in the pharmaceutical industry.

April 27, 2026 Jazz Pharmaceuticals Announces FDA Acceptance of Ziihera® Application Jazz Pharmaceuticals has announced the FDA's acceptance of its supplemental Biologics License Application for Ziihera®, targeting HER2-positive gastroesophageal adenocarcinoma. The application, based on promising clinical trial results, has been designated for Priority Review, with a target action date of August 25, 2026.

April 21, 2026 Jazz Pharmaceuticals to Announce First Quarter Financial Results on May 5, 2026 Jazz Pharmaceuticals will report its Q1 2026 financial results on May 5, 2026, followed by a management-led webcast. Stakeholders can access a replay if unable to attend live.

April 21, 2026 Jazz Pharmaceuticals Set to Showcase Breakthrough Oncology Data at ASCO 2026 Jazz Pharmaceuticals is set to showcase ten presentations at ASCO 2026, highlighting innovative oncology treatments, including Ziihera for gastroesophageal adenocarcinoma and Zepzelca for small cell lung cancer. The company aims to enhance clinical practice through detailed analyses of patient outcomes and treatment effectiveness.

April 09, 2026 Jazz Pharmaceuticals to Showcase Advances in Neurology at 2026 AAN Annual Meeting Jazz Pharmaceuticals will present six abstracts at the 2026 AAN Annual Meeting, focusing on innovative treatments for epilepsy and sleep disorders. Highlights include the EpiCom Phase 3b/4 study results and findings from the DUET study on narcolepsy. The company's commitment to advancing neuroscience is evident as they address significant unmet needs in rare neurological disorders.

April 01, 2026 Jazz Pharmaceuticals to Engage in Needham Virtual Healthcare Conference Jazz Pharmaceuticals will participate in the 25th Annual Needham Healthcare Conference on April 15, 2026, featuring a fireside chat. The event will be accessible via audio webcast, reinforcing Jazz's commitment to transparency and engagement in the biopharmaceutical sector.

March 18, 2026 Jazz Pharmaceuticals Showcases Oncology Innovations at AACR 2026 Annual Meeting Jazz Pharmaceuticals will present significant oncology advancements at the AACR 2026 Annual Meeting, highlighting promising data on zanidatamab and other therapies. Key findings include impressive results from the NeoZanHER trial, showcasing the potential of their innovative drug candidates in cancer treatment.

February 24, 2026 Jazz Pharmaceuticals Reports Strong Financial Results for 2025 and Provides 2026 Guidance Jazz Pharmaceuticals reported a record revenue of $4.3 billion for 2025, marking a 5% year-over-year increase. The company anticipates continued growth in 2026, driven by key product launches and a strong R&D pipeline, particularly in oncology and epilepsy treatments.

February 24, 2026 Jazz Pharmaceuticals PLC Reports 2025 Annual Financial Results Jazz Pharmaceuticals' 2025 annual report reveals a modest revenue increase to $4.26 billion but a significant net loss of $356.1 million. The company's focus on R&D and strategic acquisitions, like Chimerix, aims to bolster its position in the competitive biopharmaceutical landscape.

February 17, 2026 Jazz Pharmaceuticals to Showcase Innovations at Upcoming Investor Conferences Jazz Pharmaceuticals will showcase its innovative therapies at the TD Cowen and Barclays investor conferences in March 2026. The fireside chats will offer insights into the company's commitment to transforming patient care and its robust pipeline of treatments for rare diseases.

February 10, 2026 Jazz Pharmaceuticals Set to Release Q4 and Full Year 2025 Financial Results Jazz Pharmaceuticals is set to release its Q4 and full year 2025 financial results on February 24, 2026, followed by a live webcast. The company emphasizes its commitment to patient care and innovative therapies for rare diseases, making this financial report significant for investors.

January 08, 2026 Jazz Pharmaceuticals Welcomes Thomas Riga as Chief Business Officer Jazz Pharmaceuticals has appointed Thomas Riga as Chief Business Officer, effective January 1, 2026. With over 25 years of experience, Riga aims to strengthen corporate development and advance innovative therapies, particularly in oncology and neuroscience.

January 06, 2026 Jazz Pharmaceuticals Reports Groundbreaking Results from HERIZON-GEA-01 Trial The HERIZON-GEA-01 trial demonstrated unprecedented overall survival rates for Ziihera® in treating HER2+ gastroesophageal adenocarcinoma. With median overall survival exceeding two years, these findings could redefine first-line treatment standards.

December 17, 2025 Jazz Pharmaceuticals to Showcase Innovations at Upcoming Investor Events Jazz Pharmaceuticals will present key findings from the zanidatamab HERIZON-GEA-01 trial on January 9, 2026, and will share strategic updates at the J.P. Morgan Healthcare Conference on January 13, 2026. These events mark significant milestones for the company as it showcases its commitment to innovative treatments.

December 05, 2025 Jazz Pharmaceuticals Unveils Promising New Data on Epidiolex® at AES 2025 Annual Meeting At the AES 2025 Annual Meeting, Jazz Pharmaceuticals revealed new data on Epidiolex®, emphasizing its effectiveness in treating treatment-resistant epilepsies. Highlights include the EpiCom trial's promising results and real-world effectiveness insights that underscore Epidiolex's transformative potential.

December 02, 2025 Jazz Pharmaceuticals Announces Key Data on Ziihera® at ASCO GI 2026 Jazz Pharmaceuticals will present pivotal Phase 3 results for Ziihera at ASCO GI 2026, showcasing significant advancements in treating HER2-positive gastroesophageal adenocarcinoma. The combination therapies demonstrated improved survival rates, positioning Ziihera as a potential new standard of care.

November 18, 2025 Jazz Pharmaceuticals to Engage Investors at Citi's 2025 Global Healthcare Conference Jazz Pharmaceuticals will engage with investors at Citi's 2025 Global Healthcare Conference on December 2, 2025. The fireside chat will provide insights into their strategic direction and ongoing projects in biopharmaceuticals.

November 17, 2025 Jazz Pharmaceuticals Announces Promising Phase 3 Results for Ziihera in Treating HER2-Positive Gastroesophageal Adenocarcinoma Jazz Pharmaceuticals revealed promising Phase 3 results for Ziihera in treating HER2-positive gastroesophageal adenocarcinoma, showing significant improvements in progression-free and overall survival. The company plans to file for FDA approval in 2026, aiming to establish Ziihera as a first-line treatment option.

November 11, 2025 Jazz Pharmaceuticals Unveils Promising Data for Modeyso™ in H3 K27M-Mutant Diffuse Midline Glioma Jazz Pharmaceuticals will present promising data on Modeyso™ at the SNO Annual Meeting, showcasing its potential in treating aggressive H3 K27M-mutant diffuse midline gliomas. The research highlights innovative approaches to enhance treatment responses and alter the tumor immune environment, aiming to improve outcomes for affected patients.

November 05, 2025 Jazz Pharmaceuticals Reports Record Third Quarter Revenue and Strategic Updates Jazz Pharmaceuticals achieved record revenues of $1.126 billion in Q3 2025, reflecting strong growth in products like Epidiolex and Xywav. The company also made strategic moves with new FDA approvals and product launches, including Modeyso for brain tumors. With a promising pipeline and financial outlook, Jazz is positioned for continued success.

November 05, 2025 Jazz Pharmaceuticals PLC Reports Strong Q3 2025 Performance Amidst Competitive Landscape In Q3 2025, Jazz Pharmaceuticals reported a net income of $251.4 million, driven by successful product sales and strategic acquisitions. The company faces challenges from competition and regulatory scrutiny but remains well-positioned for growth in the biopharmaceutical sector.

October 28, 2025 Jazz Pharmaceuticals Welcomes Dr. Ted W. Love to Board of Directors Jazz Pharmaceuticals has appointed Dr. Ted W. Love to its Board of Directors, effective December 1, 2025. With over 30 years in drug development, Dr. Love's expertise aligns with Jazz's commitment to innovation and patient care as part of their ongoing Board renewal strategy.

October 22, 2025 Jazz Pharmaceuticals Set to Release Third Quarter Financial Results Jazz Pharmaceuticals is set to announce its Q3 2025 financial results on November 5, 2025. A live webcast will follow the announcement, providing insights into the company's performance and strategic initiatives. Stakeholders are encouraged to register in advance for this important event.

October 02, 2025 Jazz Pharmaceuticals Achieves Milestone with FDA Approval of Zepzelca® Combination Therapy Jazz Pharmaceuticals has received FDA approval for Zepzelca® in combination with atezolizumab as a first-line maintenance treatment for extensive-stage small cell lung cancer. This new approach aims to improve patient outcomes significantly, based on strong clinical trial results.

September 22, 2025 Jazz Pharmaceuticals Unveils New Data on Xywav® at World Sleep and Psych Congresses Jazz Pharmaceuticals revealed crucial new data on Xywav at the World Sleep and Psych Congresses 2025, demonstrating its effectiveness in treating narcolepsy and idiopathic hypersomnia. The findings emphasize the importance of sodium reduction and improved patient outcomes, showcasing Xywav's potential to enhance quality of life.

September 09, 2025 Jazz Pharmaceuticals' Modeyso™ Receives Key Endorsement in Cancer Treatment Jazz Pharmaceuticals' Modeyso™ has been added to NCCN Guidelines as a key treatment for H3 K27M-mutant diffuse midline glioma. This FDA-approved therapy highlights urgent medical needs and offers hope to patients with limited options.

August 21, 2025 Jazz Pharmaceuticals to Showcase Innovations at 2025 Wells Fargo Healthcare Conference Jazz Pharmaceuticals will participate in the 2025 Wells Fargo Healthcare Conference, featuring a fireside chat to discuss their innovative approaches in biopharmaceuticals. An audio webcast will be available for those who cannot attend live, showcasing the company's commitment to transparency and patient-focused initiatives.

August 20, 2025 Jazz Pharmaceuticals to Host Investor Webcast for Modeyso™ on August 27, 2025 Jazz Pharmaceuticals will host an investor webcast on August 27, 2025, to discuss Modeyso™, the first FDA-approved treatment for a rare brain tumor. The session will feature clinical data and commercialization strategies, offering critical insights for investors.

August 20, 2025 Jazz Pharmaceuticals Expands Neuroscience Portfolio with Exclusive Licensing Agreement for SAN2355 Jazz Pharmaceuticals has entered an exclusive agreement with Saniona to develop SAN2355, a targeted treatment for epilepsy. This collaboration aims to leverage Jazz's expertise to potentially improve the treatment landscape for neurological conditions. The deal includes substantial financial incentives and positions both companies for future advancements in epilepsy care.

August 06, 2025 Jazz Pharmaceuticals PLC Reports Mixed Results in Q2 2025 Jazz Pharmaceuticals PLC reported mixed financial results for Q2 2025, showing increased revenue but a significant net loss of $718.4 million. While products like Xywav and Rylaze continue to perform, challenges from competition and high expenses raise concerns about future growth.

August 05, 2025 Jazz Pharmaceuticals Reports Solid Q2 2025 Results and Upscale Guidance Jazz Pharmaceuticals announced its Q2 2025 financial results, revealing a revenue increase and leadership transition to Renee Gala. The company is optimistic about future growth, driven by strong product performance, particularly from Xywav.

July 22, 2025 Jazz Pharmaceuticals Set to Announce Q2 2025 Financial Results Jazz Pharmaceuticals will announce its Q2 2025 financial results on August 5, 2025, followed by a live webcast for detailed discussions. Interested parties can register online.

July 10, 2025 Jazz Pharmaceuticals Appoints Renee Gala as New CEO: A Strategic Move for Growth Renee Gala has been appointed as the new CEO of Jazz Pharmaceuticals, effective August 2025, succeeding co-founder Bruce Cozadd. With over 30 years of experience, Gala aims to build on the company's momentum and focus on innovative therapies for serious diseases.

July 01, 2025 Jazz Pharmaceuticals Secures Conditional Marketing Authorization for Ziihera® in the EU Jazz Pharmaceuticals has received conditional marketing authorization from the European Commission for Ziihera® (zanidatamab), the first HER2-targeted therapy for advanced biliary tract cancer. With promising clinical trial results, Ziihera offers hope to patients facing limited treatment options and poor prognoses.

June 10, 2025 Jazz Pharmaceuticals Announces FDA Priority Review for Zepzelca® Combination Therapy Jazz Pharmaceuticals announced that the FDA has granted Priority Review for Zepzelca® in combination with atezolizumab for extensive-stage small cell lung cancer. The decision follows promising results from the Phase 3 IMforte trial, highlighting a significant advance in treatment options for this aggressive cancer type.

June 09, 2025 Jazz Pharmaceuticals Unveils Promising Phase 4 Data for Xywav® in Narcolepsy Jazz Pharmaceuticals presented promising Phase 4 data for Xywav® at SLEEP 2025, highlighting its low-sodium profile and significant cardiovascular benefits for narcolepsy patients. The XYLO study demonstrated reduced blood pressure and sodium intake, marking an important advancement in narcolepsy treatment.

June 02, 2025 Jazz Pharmaceuticals Reports Promising Results in Small Cell Lung Cancer Treatment Jazz Pharmaceuticals announced positive results from the Phase 3 IMforte study, showing significant survival benefits for extensive-stage small cell lung cancer patients using Zepzelca with atezolizumab. The findings indicate a substantial improvement in progression-free and overall survival, marking a hopeful advancement in cancer treatment.

June 02, 2025 Jazz Pharmaceuticals Reports Promising Long-Term Survival Data for Ziihera® in HER2-Positive Gastroesophageal Adenocarcinoma Jazz Pharmaceuticals reported promising Phase 2 trial results for Ziihera in HER2-positive gastroesophageal adenocarcinoma, showing a median overall survival of 36.5 months. This data suggests significant potential for Ziihera in improving outcomes for patients with this aggressive cancer type.

May 29, 2025 Jazz Pharmaceuticals Showcases Groundbreaking Research on Xywav® at SLEEP 2025 Jazz Pharmaceuticals is set to present significant research on Xywav at SLEEP 2025, showcasing its efficacy in treating narcolepsy and idiopathic hypersomnia. Key findings from multiple trials emphasize Xywav's unique low-sodium formulation and its cardiovascular safety benefits.

May 21, 2025 Jazz Pharmaceuticals to Showcase Innovations at Upcoming Investor Conferences Jazz Pharmaceuticals will participate in two key investor conferences in June 2025, highlighting its innovative pipeline and commitment to the biopharmaceutical sector. Both events will feature webcasts for broader accessibility, reinforcing the company's dedication to engaging with stakeholders.

May 07, 2025 Jazz Pharmaceuticals PLC Reports Strong Q1 2025 Performance Amid Market Challenges In Q1 2025, Jazz Pharmaceuticals reported $897.8 million in revenue despite a net loss of $92.54 million. The company focuses on innovation in neuroscience and oncology while navigating competitive pressures and regulatory challenges.

May 06, 2025 Jazz Pharmaceuticals Reports Strong Q1 2025 Results and Confirms Financial Outlook Jazz Pharmaceuticals announced its Q1 2025 results, reporting $898 million in revenues, driven by strong sales of Xywav and Epidiolex. Despite some declines in other products, the company reaffirms its financial outlook for the year, projecting revenues of $4.15-$4.40 billion.

April 30, 2025 Jazz Pharmaceuticals Set to Shine at BofA Securities 2025 Healthcare Conference Jazz Pharmaceuticals is set to participate in the BofA Securities 2025 Healthcare Conference, where they will discuss their innovative therapies and strategic initiatives. The fireside chat on May 14, 2025, will provide insights into the company's pipeline and commitment to patient care.

April 25, 2025 Jazz Pharmaceuticals Receives Positive Opinion for Zanidatamab in Europe Jazz Pharmaceuticals announced a positive opinion from the CHMP for zanidatamab, aimed at treating HER2-positive biliary tract cancer, addressing an urgent medical need. This innovative therapy could be a groundbreaking treatment option for patients facing limited options.

April 23, 2025 Jazz Pharmaceuticals Unveils Promising Data at ASCO 2025 Jazz Pharmaceuticals is set to present groundbreaking data at ASCO 2025, featuring advancements in small cell lung cancer and HER2-positive gastroesophageal cancer treatments. Key highlights include promising results from the Phase 3 IMforte trial of Zepzelca and atezolizumab, along with insights on Ziihera and investigational dordaviprone.

April 22, 2025 Jazz Pharmaceuticals Set to Release First Quarter Financial Results Jazz Pharmaceuticals is set to release its first-quarter financial results for 2025 on May 6, with a live webcast scheduled for investors. The event will provide insights into the company's performance and future strategies, highlighting its innovative biopharmaceutical initiatives.

April 21, 2025 Jazz Pharmaceuticals Completes Acquisition of Chimerix: A Strategic Move to Enhance Oncology Portfolio Jazz Pharmaceuticals has completed its $935 million acquisition of Chimerix, positioning it as a wholly owned subsidiary. This strategic move aims to enhance Jazz's oncology portfolio with dordaviprone, a promising therapy for H3 K27M-mutant diffuse glioma, set for potential FDA approval by 2025.

March 26, 2025 Jazz Pharmaceuticals Set to Shine at the 24th Annual Needham Virtual Healthcare Conference Jazz Pharmaceuticals will participate in the 24th Annual Needham Healthcare Conference on April 9, 2025, featuring a fireside chat with management. This event highlights Jazz's commitment to transparency and innovation in biopharmaceuticals, focusing on their diverse portfolio and future strategies.

March 19, 2025 Jazz Pharmaceuticals Unveils Research Breakthroughs at 2025 AAN Annual Meeting Jazz Pharmaceuticals will present seven significant abstracts at the 2025 AAN Annual Meeting, focusing on Xywav's effects on narcolepsy and idiopathic hypersomnia, along with insights on Epidiolex treatment patterns. Key findings highlight improvements in sleep quality and treatment persistence, emphasizing the company's commitment to enhancing patient outcomes.

March 05, 2025 Jazz Pharmaceuticals to Acquire Chimerix: A Strategic Move to Enhance Oncology Portfolio Jazz Pharmaceuticals has announced its acquisition of Chimerix for $935 million, aiming to strengthen its oncology portfolio with the addition of dordaviprone, a novel treatment for aggressive brain tumors. This strategic move highlights Jazz's commitment to addressing significant unmet medical needs in rare diseases and positions the company for future growth.

February 26, 2025 Jazz Pharmaceuticals PLC Reports Robust Growth in 2024 Annual Financials Jazz Pharmaceuticals PLC reported robust financial results for 2024, with a revenue increase to $4.06 billion and significant product approvals. The company's focus on innovation in neuroscience and oncology, alongside effective cost management, contributed to a 35% rise in net income, showing resilience amidst a competitive landscape.

February 20, 2025 SWOT Analysis of Jazz Pharmaceuticals PLC in 2025 This SWOT analysis assesses Jazz Pharmaceuticals PLC's strategic position in 2025, detailing its strengths in innovative therapies, weaknesses from legal challenges, opportunities for growth, and threats from competition. It provides insights into how the company can navigate its market landscape.

February 20, 2025 Jazz Pharmaceuticals to Showcase Innovations at TD Cowen's 45th Annual Health Care Conference Jazz Pharmaceuticals will participate in TD Cowen's 45th Annual Health Care Conference on March 5, 2025, featuring a fireside chat with company leadership. The event will highlight their commitment to patient-centric solutions and showcase ongoing research in oncology and neuroscience.

February 11, 2025 Jazz Pharmaceuticals Set to Report 2024 Financial Results Jazz Pharmaceuticals is set to release its 2024 financial results on February 25, 2025, followed by a live audio webcast. Investors and analysts can gain insights into the company's performance and future plans.

November 07, 2024 Jazz Pharmaceuticals PLC Reports Strong Q3 2024 Financial Results Jazz Pharmaceuticals PLC reported impressive Q3 2024 results with $1.05 billion in revenue and a net income of $215 million. The company saw significant growth in Xywav sales, despite competition affecting Xyrem. With a solid balance sheet, Jazz continues to focus on innovation and market expansion.

August 01, 2024 Jazz Pharmaceuticals PLC Reports Strong Q2 2024 Financial Results Jazz Pharmaceuticals PLC reported impressive Q2 2024 financial results, achieving revenues of $1.26 billion, up from $1.19 billion YoY. The company is advancing key projects in oncology and neuroscience while managing increased costs due to R&D investments.

May 02, 2024 Jazz Pharmaceuticals PLC Reports Strong Q1 2024 Performance Amidst Competitive Challenges Jazz Pharmaceuticals PLC reported a strong Q1 2024, achieving $1.3 billion in revenue, a 14% increase year-over-year. Key drivers included robust sales of Xywav and growth in both Neuroscience and Oncology segments. Despite challenges in competition and market sustainability, the company remains focused on innovation and R&D.

Jazz Pharmaceuticals to Showcase Innovations at Upcoming Investor Conferences

Last updated: May 21, 2025 •

Taurigo

1. Engagement with the Investment Community

On May 21, 2025, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) made a significant announcement regarding its participation in two prominent investor conferences scheduled for June 2025. This initiative underscores the company's commitment to engaging with the investment community and highlighting its innovative pipeline in the biopharmaceutical sector.

Conference Details

Jazz Pharmaceuticals will feature in the following events:

Jefferies Global Healthcare Conference: Scheduled for Thursday, June 5, 2025, the conference will include a fireside chat at 6:55 a.m. PDT / 9:55 a.m. EDT / 2:55 p.m. IST.

Goldman Sachs 46th Annual Global Healthcare Conference: Taking place on Wednesday, June 11, 2025, this event will also consist of a fireside chat at 7:00 a.m. PDT / 10:00 a.m. EDT / 3:00 p.m. IST.

These conferences are vital platforms for Jazz Pharmaceuticals to connect with investors, showcasing its strategic direction, innovative research, and development efforts aimed at transforming patient care.

Listening Options for Investors

For those unable to attend the live presentations, Jazz Pharmaceuticals will provide audio webcasts of both events. These webcasts will be accessible via the Investors section of the company’s website, allowing stakeholders to stay informed on the latest developments. A replay of the webcasts will be archived for 30 days, ensuring broader access to the information shared during the conferences.

2. Jazz Pharmaceuticals: A Leader in Biopharma Innovation

Jazz Pharmaceuticals is renowned for its dedication to improving the lives of patients suffering from serious diseases. With a diverse portfolio that includes leading therapies for sleep disorders, epilepsy, and a growing array of cancer treatments, the company is at the forefront of biopharmaceutical innovation.

Headquartered in Dublin, Ireland, Jazz Pharmaceuticals boasts a global presence, with research and development laboratories and manufacturing facilities situated in multiple countries. The company's commitment to a patient-focused and science-driven approach enables it to pioneer advancements across its robust pipeline, particularly in oncology and neuroscience.

Conclusion

As Jazz Pharmaceuticals prepares to engage with the investment community through these upcoming conferences, it continues to solidify its position as a leader in the biopharmaceutical landscape. Investors and stakeholders are encouraged to tune in to the webcasts for insights into the company’s future directions and innovations that aim to address unmet medical needs around the world. For more information, interested parties can visit Jazz Pharmaceuticals' official website.

Original press release

You may also be interested in: